U.S. drugmaker Acceleron Pharma Inc is in advanced talks to be acquired by a large pharmaceutical company for more than $11 billion, Bloomberg News reported on Friday, citing people familiar with the matter.
The acquisition would be made at about $180 per share in cash, the report said.
Details about the potential buyer were not known, but the report added that several global drugmakers, including Bristol-Myers Squibb Co, which owns 11.5% of Acceleron's stock, are seen as potential suitors.
Acceleron did not immediately respond to Reuters' request for comment.
Acceleron, based in Cambridge, Massachusetts is a clinical-stage biopharmaceutical company with a total market value of $10.2 billion. The company focuses on the discovery, development and commercialization of therapeutics to treat serious and rare diseases